8-Isoprostaglandin E2-d4

8-Isoprostaglandin E2-d4

• UNSPSC Description: 8-Isoprostaglandin E2-d4 (iPE2-III-d4) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway[1][2].
• Target Antigen: Isotope-Labeled Compounds; Prostaglandin Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Others
• Field of Research: Cardiovascular Disease
• Smiles: CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC([C@H]1C/C=C\C([2H])([2H])C([2H])([2H])CC(O)=O)=O
• Molecular Weight: 356.49
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Wilson SJ, et al. Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem Biophys Res Commun. 2007;352(2):397-403. |[3]Tintut Y, et al. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem. 2002;277(16):14221-14226.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported